The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

May

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Behind the Scenes of the 2026 ASCO Annual Meeting

First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations

FDA Approves Durvalumab Plus BCG for High-Risk NMIBC

Local Radiotherapy May Help Control Oligometastatic Breast Cancer

TAILORx and RxPONDER Trials Shift to a Discovery Platform